EUVIMEDEUVIMED entdecken
VergleichsstudieKohortenstudieOpen Access · CC BY-NC-ND 4.0

Head‐to‐head comparison of treatment sequences in advanced pancreatic cancer—Real‐world data from the prospective German TPK clinical cohort study

Norbert Marschner iD, Nina Haug, Susanna Hegewisch-Becker, Marcel Reiser, Steffen Dörfel, Christian Lerchenmüller, Hartmut Linde, Thomas Wolf, Anna Hof, Anja Kaiser-Osterhues, Karin Potthoff, Martina Jänicke und 1 weitere

International Journal of Cancer · 2024

DOI: 10.1002/ijc.35071 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift International Journal of Cancer, 2024. Verfasst von Norbert Marschner und 12 weiteren Autor:innen. Beteiligte Einrichtung: Med. Klinik 1, Universitätsklinik Freiburg, Freiburg, Germany. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Fluorouracil, Leucovorin. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

There are no clear guidelines regarding the optimal treatment sequence for advanced pancreatic cancer, as head‐to‐head phase III randomised trials are missing. We assess real‐world effectiveness of three common sequential treatment strategies by emulating a hypothetical randomised trial. This analysis included 1551 patients with advanced pancreatic cancer from the prospective, clinical cohort study Tumour Registry Pancreatic Cancer receiving FOLFIRINOX ( n = 613) or gemcitabine/nab‐paclitaxel (GEMNAB; n = 938) as palliative first‐line treatment. We used marginal structural modelling to compare overall survival (OS) and time to deterioration (TTD) of health‐related quality of life (HRQoL) between three common first‐ to second‐line treatment sequences, adjusting for time‐varying potential confounding. The sequences were: FOLFIRINOX→GEMNAB, GEMNAB→FOLFOX/OFF and GEMNAB→nanoliposomal irinotecan (NALIRI) + 5‐fluorouracil. Outcome was also calculated stratified by patients' prognostic risk according to the Pancreatic Cancer Score. Median OS and TTD of HRQoL independent of risk were 10.7 [8.9, 11.9] and 6.4 [4.8, 7.7] months for FOLFIRINOX→GEMNAB, 8.4 [7.4, 9.7] and 5.8 [4.6, 7.1] months for GEMNAB→FOLFOX/OFF and 8.9 [7.8, 10.4] and 4.6 [4.1, 6.1] months for GEMNAB→NALIRI+5‐fluorouracil. Compared to FOLFIRINOX→GEMNAB, OS and TTD were worse for poor‐risk patients with GEMNAB→FOLFOX/OFF (OS: HR 2.09 [1.47, 2.98]; TTD: HR 1.97 [1.19, 3.27]) and those with GEMNAB→NALIRI+5‐fluorouracil (OS: HR 1.35, [0.76, 2.39]; TTD: HR 2.62 [1.56, 4.42]). Brackets denote 95%‐confidence intervals. The estimated real‐world effectiveness of the three treatment sequences evaluated were largely comparable. Poor‐risk patients might benefit from intensified treatment with FOLFIRINOX→GEMNAB in terms of clinical and patient‐reported outcomes. Future randomised trials on sequential treatments in advanced pancreatic cancer are warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsFluorouracilLeucovorinIrinotecanQuality of LifeGemcitabinePaclitaxelOxaliplatinDeoxycytidineHumansMaleFemaleMiddle AgedAgedProspective StudiesAlbuminsGermanyOrganoplatinum CompoundsAdultTreatment OutcomePrognosis

Stichwörter der Autor:innen

FOLFIRINOXcohort studiesgemcitabine/nab‐paclitaxelpancreatic carcinomasequential treatment

Substanzen

FluorouracilLeucovorinIrinotecanGemcitabinePaclitaxelOxaliplatinDeoxycytidinefolfirinox130-nm albumin-bound paclitaxelAlbumins

Autor:innen und Institutionen

  • Med. Klinik 1, Universitätsklinik Freiburg, Freiburg, Germany.
  • iOMEDICO, Freiburg, Germany.
  • Biostatistics, iOMEDICO, Freiburg, Germany.
  • Hämatologisch-Onkologische Praxis Eppendorf (HOPE), Hamburg, Germany.
  • PIOH-Praxis Internistische Onkologie und Hämatologie, Köln, Germany.
  • Onkozentrum Dresden/Freiberg, Dresden, Germany.

ORCID-Profile: Norbert Marschner

Zitieren

APA

Marschner, N., Haug, N., Hegewisch-Becker, S., Reiser, M., Dörfel, S., Lerchenmüller, C., Linde, H., Wolf, T., Hof, A., Kaiser-Osterhues, A., Potthoff, K., Jänicke, M., & TPK‐Group (Tumour Registry Pancreatic Cancer) (2024). Head‐to‐head comparison of treatment sequences in advanced pancreatic cancer—Real‐world data from the prospective German TPK clinical cohort study. International Journal of Cancer. https://doi.org/10.1002/ijc.35071

Vancouver

Marschner N, Haug N, Hegewisch-Becker S, Reiser M, Dörfel S, Lerchenmüller C, et al. Head‐to‐head comparison of treatment sequences in advanced pancreatic cancer—Real‐world data from the prospective German TPK clinical cohort study. International Journal of Cancer. 2024. doi:10.1002/ijc.35071

BibTeX
@article{Marschner2024,
  author = {Marschner, Norbert and Haug, Nina and Hegewisch-Becker, Susanna and Reiser, Marcel and Dörfel, Steffen and Lerchenmüller, Christian and Linde, Hartmut and Wolf, Thomas and Hof, Anna and Kaiser-Osterhues, Anja and Potthoff, Karin and Jänicke, Martina and TPK‐Group (Tumour Registry Pancreatic Cancer), TPK‐Group (Tumour Registry Pancreatic Cancer)},
  title = {Head‐to‐head comparison of treatment sequences in advanced pancreatic cancer—Real‐world data from the prospective German TPK clinical cohort study},
  journal = {International Journal of Cancer},
  year = {2024},
  doi = {10.1002/ijc.35071}
}
Kostenlos starten →